A Study of LY3502970 in Healthy Participants

NCT03929744 · Completed

Last updated 2026-05-28

This study tests the safety of the experimental drug LY3502970 in healthy adults by monitoring for any serious side effects.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 133 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2019-06 · est. completion 2020-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03929744 ↗

Description as written by the study sponsor.

The main purposes of this study are to determine: * The safety of LY3502970 and any side effects that might be associated with it. * How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.

Treatments tested

LY3502970 Drug

Administered orally.
Placebo Drug

Administered orally.
Atorvastatin Drug

Administered orally.
Simvastatin Drug

Administered orally.
Midazolam Drug

Administered orally.

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03929744 ↗